Drug Profile
Research programme: dengue vaccine - Sentinext Therapeutics
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Sentinext Therapeutics
- Class Dengue vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dengue
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Dengue in Malaysia (Parenteral, Injection)
- 04 Oct 2012 Early research in Dengue in Malaysia (Parenteral)